Neurology
Parkinson's Disease & Dopamine
Nigrostriatal neuron loss, Lewy bodies, and the L-DOPA bridge
Parkinson's disease is a progressive neurodegenerative disorder caused by death of dopaminergic neurons in the substantia nigra. Motor symptoms emerge only after 60-80% have already died. The pathological hallmark is the Lewy body, an aggregate of misfolded α-synuclein.
- Cell death threshold60-80% nigral loss before motor symptoms
- Prevalence (age 60+)~1% globally; ~10M worldwide
- Hallmark pathologyLewy bodies (α-synuclein aggregates)
- First-line therapyL-DOPA + carbidopa (since 1967)
- Cardinal motor signsTremor · rigidity · bradykinesia · postural instability
- Median onset~60 years; ~5% under age 50
Interactive visualization
Press play, or step through manually. The visualization is yours to drive — try it before reading on.
Watch the 60-second explainer
A condensed visual walkthrough — narrated, captioned, under a minute.
How it works
Voluntary movement is gated by a feedback loop between the cortex and the basal ganglia. The substantia nigra pars compacta sends dopamine into the striatum (caudate + putamen) through the nigrostriatal tract. Dopamine acts at D1 receptors to facilitate the "direct pathway" (movement go) and at D2 receptors to suppress the "indirect pathway" (movement stop). Without dopamine, the indirect pathway becomes overactive: the subthalamic nucleus and globus pallidus interna ramp up inhibition of the thalamus, and motor cortex output collapses. The clinical picture is a brake that won't release — slow movement, rigid muscle tone, and a low-frequency tremor that appears at rest.
Pathologically, the disease begins decades before diagnosis. Misfolded α-synuclein seeds prion-like aggregation, recruiting normal monomers into fibrils. The fibrils gather into Lewy bodies that interfere with mitochondrial function, proteasomal degradation, and synaptic vesicle release. Pigmented dopaminergic neurons in the substantia nigra are particularly vulnerable — their long, branched, energy-hungry axons and oxidative dopamine metabolism create a perfect storm of stress.
Worked clinical example
A 64-year-old engineer notices that his right hand feels "stiff" when buttoning a shirt. Over six months, family members spot that his right arm doesn't swing when he walks. On examination he has a 4-Hz resting tremor of the right thumb, cogwheel rigidity at the right wrist, and slowed finger-tapping (bradykinesia). His handwriting has shrunk (micrographia). He admits to acting out vivid dreams for years and losing his sense of smell. The pattern — asymmetric onset, rest tremor, REM sleep behavior disorder, anosmia — is classic. A DAT-SPECT scan shows reduced dopamine-transporter binding in the left putamen. He starts carbidopa-levodopa 25/100 mg three times daily. Within two weeks the tremor halves and his handwriting recovers. This robust L-DOPA response confirms idiopathic Parkinson's; atypical parkinsonisms (multiple system atrophy, progressive supranuclear palsy) respond poorly.
Treatment pipeline
- L-DOPA + carbidopa — the most effective symptomatic drug for 55+ years; carbidopa blocks peripheral conversion, sparing more for the brain.
- Dopamine agonists (pramipexole, ropinirole, rotigotine patch) — bypass dying neurons by directly stimulating D2/D3 receptors; impulse-control side effects (gambling, hypersexuality) in ~14%.
- MAO-B inhibitors (selegiline, rasagiline) — slow dopamine breakdown in the cleft; modest symptomatic effect.
- COMT inhibitors (entacapone) — extend the L-DOPA half-life by blocking peripheral O-methylation.
- Deep brain stimulation — high-frequency stimulation of the subthalamic nucleus or globus pallidus interna for advanced motor fluctuations.
- Focused ultrasound thalamotomy — incisionless lesion for tremor-dominant disease.
- Disease-modifying candidates — anti-α-synuclein antibodies (prasinezumab, cinpanemab), GBA1 chaperones, LRRK2 kinase inhibitors. None yet proven to slow progression in late-stage trials.
Common pitfalls
- Treating tremor in isolation. Essential tremor (postural, bilateral, alcohol-responsive) is far more common and is not Parkinson's. The rule: rest tremor + bradykinesia + asymmetry = Parkinson's; postural/action tremor + no bradykinesia = essential tremor.
- Holding L-DOPA "until you really need it." Old dogma. Modern data show L-DOPA is not neurotoxic and delaying treatment delays only function, not progression.
- Mistaking motor fluctuations for new disease. "Wearing off" and dyskinesias after 5-10 years reflect the shrinking buffering capacity of dying neurons, not a treatment failure.
- Anticholinergic overuse in the elderly. Trihexyphenidyl can help tremor in young patients but causes confusion, hallucinations, and dementia in older ones.
- Missing drug-induced parkinsonism. Antipsychotics (haloperidol, risperidone) and antiemetics (metoclopramide, prochlorperazine) block D2 receptors and mimic Parkinson's. Always review the medication list.
| Feature | Parkinson's disease | Essential tremor |
|---|---|---|
| Tremor type | Rest (disappears with action) | Postural / action (worse with use) |
| Frequency | 4-6 Hz | 6-12 Hz |
| Symmetry | Asymmetric onset | Bilateral, often symmetric |
| Bradykinesia | Yes (defining feature) | No |
| Rigidity | Yes (cogwheel) | No |
| Alcohol response | None | Often dramatic relief |
| First-line drug | L-DOPA / carbidopa | Propranolol or primidone |
Frequently asked questions
Why do symptoms appear so late?
The basal ganglia have substantial reserve capacity. Up to 60-80% of substantia nigra dopaminergic neurons must die — and striatal dopamine fall by 80%+ — before resting tremor, rigidity, and bradykinesia cross the clinical threshold. This long pre-motor phase (often 10-20 years) features non-motor signs like REM sleep behavior disorder, anosmia, and constipation. Most disease-modifying trials may fail because they begin too late, after the bulk of neurons are already lost.
What exactly is a Lewy body?
A spherical eosinophilic inclusion inside neuronal cell bodies, composed largely of misfolded α-synuclein protein. Friedrich Lewy described them in 1912. Normal α-synuclein helps regulate synaptic vesicle release, but when it misfolds into β-sheet fibrils it forms toxic aggregates. Lewy bodies are diagnostic of Parkinson's at autopsy, and the same pathology defines Lewy body dementia. Mutations in the SNCA gene (encoding α-synuclein) cause hereditary forms — but most Parkinson's is sporadic.
How does L-DOPA actually work?
Dopamine itself cannot cross the blood-brain barrier. L-DOPA (levodopa), its precursor, can — using the LAT1 large neutral amino acid transporter. Once in the brain, surviving dopaminergic neurons (and other cells) decarboxylate L-DOPA to dopamine via DDC (dopa decarboxylase). L-DOPA is given with carbidopa, a peripheral DDC inhibitor that does not cross the BBB, so less L-DOPA is converted in the gut and bloodstream — more reaches the brain, and nausea is reduced. After 5-10 years, motor fluctuations and dyskinesias emerge as the substrate of surviving neurons shrinks.
What about deep brain stimulation?
DBS implants electrodes typically in the subthalamic nucleus (STN) or globus pallidus interna (GPi) and delivers high-frequency electrical stimulation. The effect mimics a reversible lesion of the overactive output node, restoring more normal basal ganglia flow. DBS dramatically reduces tremor, rigidity, and L-DOPA-induced dyskinesia but does not slow disease progression. Best candidates have clear L-DOPA responsiveness but disabling motor fluctuations.
Is Parkinson's genetic?
About 10-15% of cases are familial. Key genes: SNCA (α-synuclein, dominant), LRRK2 (dominant, especially in Ashkenazi Jews and North African Berbers), GBA (heterozygous mutations triple Parkinson's risk, also cause Gaucher disease), PARK7, PINK1, PRKN (recessive, early-onset). Most cases are sporadic, influenced by age, environmental exposures (pesticides like paraquat, MPTP, heavy metals), traumatic brain injury, and the gut microbiome.
What are the non-motor symptoms?
Often appear years before tremor: REM sleep behavior disorder (acting out dreams — 80%+ progress to Parkinson's or related synucleinopathy), loss of smell (anosmia), constipation, depression, anxiety, cognitive slowing, autonomic dysfunction (orthostatic hypotension, urinary urgency, sexual dysfunction). Late-stage dementia affects about 80% of patients. The Braak staging hypothesis proposes pathology starts in the olfactory bulb and dorsal motor vagus, ascending into the brainstem before reaching the substantia nigra.
Why does the substantia nigra appear black?
Healthy nigral dopaminergic neurons contain neuromelanin — a dark pigment formed as a byproduct of dopamine metabolism. On a fresh brain section, the substantia nigra is visibly black, hence the name (Latin: 'black substance'). In Parkinson's, this region depigments as the pigmented neurons die. The contrast is dramatic at autopsy — a Parkinson's brain shows pale, gray nigra instead of the rich black of a healthy one. MRI neuromelanin-sensitive sequences can now image this loss in life.